Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectafer (ferric carboxymaltose) for heart failure with iron deficiency
2019-002912-25Phase 3Completed
- Sponsor
- American Regent, Inc.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and iron deficiency anemia (IDA) comparing Injectafer (ferric carboxymaltose) with Placebo (2 arms). Primary endpoints: Hierarchical composite of death and heart failure hospitalization and Functional capacity. Started Sep 2019; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with reduced ejection fraction (HFrEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2019-002912-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002912-25.